📰 ReutersReutersCodex · 实盘不做把握 6/10
北京时间·🕒 发布 20:11:22时区推断·⟳ 抓取 20:12:07·⚡ 决策 08-05 22:24:42 +2h12m·82.9 天前
Insulet下调2026年销售增长指引，美国Omnipod胰岛素泵销售放缓
Insulet将2026年收入增长指引从21%-23%下调至20%-22%，美国Omnipod销售增长指引从20%-22%下调至17%-19%，核心美国业务增速放缓是明确负面增量。
📄 原文Reuters↗ 原文
Insulet (PODD.O) lowered its annual sales growth forecast on Wednesday, pointing to a softer second half of 2026 partic…
不做 Insulet（PODD.US）
核心美国Omnipod增长指引下修是净利空，但盘前已跌超12%，且Q2收入/EPS超预期、全年利润和国际销售指引上调形成对冲，当前10:21 ET追空的风险收益不够好；仅保留风控风险。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 本地信号库已抓到Reuters原文《IT solutions provider CDW's shares fall on margin miss》，发布时间早于当前社媒/聚合转述，用作本次催化首发锚点。
- Reuters报道Insulet下调全年收入和美国Omnipod销售增长指引，并引述J.P. Morgan认为美国增长放缓担忧已提前出现。市场反应:报道称PODD盘前下跌超过12%。
关键理由
- Insulet将2026年收入增长指引从21%-23%下调至20%-22%，美国Omnipod销售增长指引从20%-22%下调至17%-19%，核心美国业务增速放缓是明确负面增量。
- Omnipod二季度销售7.959亿美元，占总收入8.017亿美元约99%，其中美国销售5.441亿美元占总收入约68%，因此美国Omnipod增速下修会直接压低2027年高成长估值预期。
- 但二季度收入和调整后EPS均超预期、全年调整后利润增长指引上调至30%以上，且股票盘前已跌超12%，当前追空的剩余edge不足。
主要风险
- 若后续电话会确认新患者增长放缓或2027年美国增长接近10%，PODD仍可能继续被下修估值。
- 反向风险是国际Omnipod指引上修和利润率改善可能促使空头回补。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-05 · 影响 weakens
Insulet二季度收入和调整后EPS均高于预期，且上调全年调整后利润增长和国际Omnipod增长指引，削弱追空确定性。
检索:Insulet Q2 2026 adjusted EPS revenue beat raised profit forecast international Omnipod guidance 原文 ↗
原文全文
展开原文 · 1,779 字
Insulet (PODD.O) lowered its annual sales growth forecast on Wednesday, pointing to a softer second half of 2026 particularly for U.S. sales of its Omnipod insulin pumps, sending shares of the company down more than 12% before the bell.
The medical-device maker now expects 2026 revenue to grow 20% to 22%, compared with its previous forecast of 21% to 23%.
Insulet cut its U.S. Omnipod sales growth forecast to between 17% and 19% from 20% to 22%, while raising its international forecast to between 30% and 32% from 26% to 28%.
"While we are updating our outlook to reflect what we’re learning as we scale in type 2 (diabetes), our conviction in the long-term opportunity remains unchanged," CEO Ashley McEvoy said.
Omnipod is a wearable insulin pump that delivers insulin without tubes and reduces the need for daily injections. Sales have grown since Omnipod 5 gained U.S. approval for people with both type 1 and type 2 diabetes.
"Investors have been worried about a steep fall off in growth from patch pump competition next year, but we’re starting to see it today already," said J.P. Morgan analyst Robbie Marcus.
"With decelerating trends in 2H, and assuming this wasn’t a record new patient quarter again, this will stoke investor fears that US growth could fall out near 10% or even lower in 2027," Marcus added.
Quarterly Omnipod sales rose 24.6% to $795.9 million, with U.S. sales increasing 20.1% to $544.1 million.
Insulet posted second-quarter adjusted profit of $1.66 per share, above analysts' estimate of $1.45, according to data compiled by LSEG. Quarterly revenue rose 23.5% to $801.7 million, beating estimates of $787.2 million.
The company raised its annual adjusted profit growth forecast to more than 30% from more than 25%.
The medical-device maker now expects 2026 revenue to grow 20% to 22%, compared with its previous forecast of 21% to 23%.
Insulet cut its U.S. Omnipod sales growth forecast to between 17% and 19% from 20% to 22%, while raising its international forecast to between 30% and 32% from 26% to 28%.
"While we are updating our outlook to reflect what we’re learning as we scale in type 2 (diabetes), our conviction in the long-term opportunity remains unchanged," CEO Ashley McEvoy said.
Omnipod is a wearable insulin pump that delivers insulin without tubes and reduces the need for daily injections. Sales have grown since Omnipod 5 gained U.S. approval for people with both type 1 and type 2 diabetes.
"Investors have been worried about a steep fall off in growth from patch pump competition next year, but we’re starting to see it today already," said J.P. Morgan analyst Robbie Marcus.
"With decelerating trends in 2H, and assuming this wasn’t a record new patient quarter again, this will stoke investor fears that US growth could fall out near 10% or even lower in 2027," Marcus added.
Quarterly Omnipod sales rose 24.6% to $795.9 million, with U.S. sales increasing 20.1% to $544.1 million.
Insulet posted second-quarter adjusted profit of $1.66 per share, above analysts' estimate of $1.45, according to data compiled by LSEG. Quarterly revenue rose 23.5% to $801.7 million, beating estimates of $787.2 million.
The company raised its annual adjusted profit growth forecast to more than 30% from more than 25%.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。